Evidence map›Paper›PMID 28558143›Full record

ArticleJournal of mass spectrometry : JMS2017

Parsing disease-relevant protein modifications from epiphenomena: perspective on the structural basis of SOD1-mediated ALS.

N D Schmitt, J N Agar

Open access · greenAbstract read
In one paragraph

Article in Journal of mass spectrometry : JMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Top-down proteomics.Nature reviews. Methods primers · 2024
    Article
  9. Novel Strategies to Address the Challenges in Top-Down Proteomics.Journal of the American Society for Mass Spectrometry · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. How many human proteoforms are there?Nature chemical biology · 2018
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

N D SchmittDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5815-2627
J N AgarDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.
Northeastern University · US

Funding

Structural Consequences of ALS-related Modifications of SOD1R01NS065263 · NINDS · NORTHEASTERN UNIVERSITY · PI AGAR, JEFFREY NEIL · 2009 to 2013
$1.7M
Stabilizing fALS SOD1 Variants by Crosslinking SubunitsR21NS071256 · NINDS · BRANDEIS UNIVERSITY · PI AGAR, JEFFREY NEIL · 2010 to 2011
$431k
NINDS NIH HHS R01 NS065263NINDS NIH HHS R21 NS071256
6 · The paper itself

Abstract

Conformational change and modification of proteins are involved in many cellular functions. However, they can also have adverse effects that are implicated in numerous diseases. How structural change promotes disease is generally not well-understood. This perspective illustrates how mass spectrometry (MS), followed by toxicological and epidemiological validation, can discover disease-relevant structural changes and therapeutic strategies. We (with our collaborators) set out to characterize the structural and toxic consequences of disease-associated mutations and post-translational modifications (PTMs) of the cytosolic antioxidant protein Cu/Zn-superoxide dismutase (SOD1). Previous genetic studies discovered >180 different mutations in the SOD1 gene that caused familial (inherited) amyotrophic lateral sclerosis (fALS). Using hydrogen-deuterium exchange with mass spectrometry, we determined that diverse disease-associated SOD1 mutations cause a common structural defect - perturbation of the SOD1 electrostatic loop. X-ray crystallographic studies had demonstrated that this leads to protein aggregation through a specific interaction between the electrostatic loop and an exposed beta-barrel edge strand. Using epidemiology methods, we then determined that decreased SOD1 stability and increased protein aggregation are powerful risk factors for fALS progression, with a combined hazard ratio > 300 (for comparison, a lifetime of smoking is associated with a hazard ratio of ~15 for lung cancer). The resulting structural model of fALS etiology supported the hypothesis that some sporadic ALS (sALS, ~80% of ALS is not associated with a gene defect) could be caused by post-translational protein modification of wild-type SOD1. We developed immunocapture antibodies and high sensitivity top-down MS methods and characterized PTMs of wild-type SOD1 using human tissue samples. Using global hydrogen-deuterium exchange, X-ray crystallography and neurotoxicology, we then characterized toxic and protective subsets of SOD1 PTMs. To cap this perspective, we present proof-of-concept that post-translational modification can cause disease. We show that numerous mutations (N➔D; Q➔E), which result in the same chemical structure as the PTM deamidation, cause multiple diseases. Copyright © 2017 John Wiley & Sons, Ltd.

Indexed as

Amyotrophic Lateral SclerosisBinding SitesComputer SimulationCrystallography, X-RayEpidemiologic MethodsHumansMass SpectrometryModels, MolecularMutationProof of Concept StudyProtein BindingProtein ConformationProtein Processing, Post-TranslationalProteolysisStatic ElectricitySuperoxide Dismutase-1Superoxide Dismutase-1ALSAlzheimer's diseaseCu/Zn-superoxide dismutaseDeamidationMass spectrometryNeurodegenerative disordersPost-translational modificationSOD1

Identifiers

PMID28558143
PMCPMC6002871
OpenAlexW2734586273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.